10-Q: PowerUp Acquisition Corp. Reports Q1 2024 Results Amidst Merger Efforts and Extension

PowerUp Acquisition Corp. reported a net loss for Q1 2024 as it continues to pursue a business combination with Visiox Pharmaceuticals and secured an extension to complete the deal.

Summary

• PowerUp Acquisition Corp. reported a net loss of $2,467,101 for the three months ended March 31, 2024, compared to a net income of $2,872,433 for the same period in 2023.
• The company's operating expenses increased significantly to $2,522,678 in Q1 2024 from $324,565 in Q1 2023.
• Interest income from the Trust Account decreased to $234,853 in Q1 2024 from $3,196,998 in Q1 2023.
• The company's total assets were $20,201,599 as of March 31, 2024, including $20,136,022 held in a trust account.
• The company has a working capital deficit of $2,567,806 as of March 31, 2024.
• PowerUp has extended its deadline to complete a business combination to February 17, 2025.
• The company is pursuing a merger with Visiox Pharmaceuticals, with a potential earnout of 6,000,000 shares based on milestones.
• The company has entered into loan and transfer agreements with various lenders, resulting in a loan and transfer note payable of $217,232 as of March 31, 2024.
• The company has also entered into subscription agreements with investors, resulting in a financial liability of $1,782,202 as of March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has secured an extension and is actively pursuing a merger, the significant net loss, increased operating expenses, and working capital deficit raise concerns. The reliance on additional financing and the uncertainty surrounding the merger outcome contribute to a negative sentiment.

Positives

• The company successfully extended the deadline to complete a business combination to February 17, 2025, providing more time to finalize the merger with Visiox Pharmaceuticals.
• The company has secured additional funding through loan and transfer agreements and subscription agreements, which will help support operations and the merger process.
• The company is actively pursuing a merger with Visiox Pharmaceuticals, which could provide a significant opportunity for growth and value creation.

Negatives

• The company experienced a significant net loss of $2,467,101 in Q1 2024, a sharp decline from the net income of $2,872,433 in Q1 2023.
• Operating expenses increased substantially to $2,522,678 in Q1 2024, indicating higher costs associated with the business combination process.
• Interest income from the Trust Account decreased significantly to $234,853 in Q1 2024, impacting the company's overall financial performance.
• The company has a working capital deficit of $2,567,806, which raises concerns about its short-term financial stability.
• The company is reliant on additional loans and investments from its sponsor, shareholders, officers, directors, or third parties to meet its working capital needs.

Risks

• The company's ability to continue as a going concern is in doubt due to its working capital deficit and the need for additional financing.
• The company may not be able to complete the business combination with Visiox Pharmaceuticals by the extended deadline of February 17, 2025.
• The company is subject to risks associated with early-stage and emerging growth companies.
• The company's financial performance is heavily dependent on the success of the proposed merger with Visiox Pharmaceuticals.
• The company may face challenges in raising additional capital on commercially acceptable terms.
• The company's share price may be volatile due to the uncertainty surrounding the business combination and the company's financial performance.

Future Outlook

The company is focused on completing its business combination with Visiox Pharmaceuticals by the extended deadline of February 17, 2025. The company may need to raise additional capital to support its operations and the merger process. The success of the merger and the future performance of the combined entity will depend on various factors, including market conditions, regulatory approvals, and the execution of the business plan.

Management Comments

• The company's management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Warrants.
• The company's officers, directors and New Sponsor may, but are not obligated to, loan the Company funds to meet the Companys working capital needs.

Industry Context

The document reflects the typical challenges faced by SPACs, including the need to secure a suitable merger target, manage operating expenses, and maintain sufficient liquidity. The extension of the deadline to complete a business combination is a common occurrence in the SPAC market, as companies seek to find the right opportunity. The company's focus on the pharmaceutical industry aligns with the current trend of SPACs targeting high-growth sectors.

Comparison to Industry Standards

• The decrease in interest income from the trust account is typical for SPACs that have moved from holding treasury securities to interest-bearing demand deposit accounts, which generally yield lower returns.
• The increase in operating expenses is common for SPACs as they progress through the merger process, incurring costs related to due diligence, legal, and financial advisory services.
• The working capital deficit is not uncommon for SPACs that are nearing their deadline to complete a business combination, as they may have limited operating revenue and ongoing expenses.
• The reliance on sponsor loans and additional investments is a standard practice for SPACs to bridge funding gaps and support their operations.
• The earnout structure in the merger agreement is a common mechanism to align the interests of the target company's shareholders with the performance of the combined entity.
• The company's financial performance is comparable to other SPACs in the pre-merger stage, which typically report losses and limited revenue.

Management Changes

Related Party Transactions

• The Original Sponsor purchased 8,625,000 shares of the company's Class B ordinary shares for $25,000.
• The company agreed to pay an affiliate of the Original Sponsor a monthly fee of $10,000 for office space, secretarial and administrative services.
• The New Sponsor purchased shares and warrants from the Original Sponsor for $1.00.
• The company entered into loan and transfer agreements with the Sponsor and various lenders.
• The company has outstanding working capital loans from the New Sponsor.

Stakeholder Impact

• Shareholders may experience dilution if additional shares are issued to finance the merger or as part of the earnout.
• Shareholders may face uncertainty regarding the future performance of the combined entity.
• Employees of both PowerUp and Visiox may experience changes in their roles and responsibilities following the merger.
• Customers of Visiox may benefit from the increased resources and capital available to the combined entity.
• Creditors of PowerUp may be impacted by the terms of the merger and any related financing arrangements.
• Suppliers of Visiox may see changes in their contracts and relationships with the combined entity.

Next Steps

• The company will continue to pursue the business combination with Visiox Pharmaceuticals.
• The company will seek to obtain necessary approvals for the merger.
• The company may need to raise additional capital to support its operations and the merger process.
• The company will work to meet the conditions for the closing of the merger agreement.

Key Dates

Keywords

SPAC, Merger, Acquisition, Business Combination, Visiox Pharmaceuticals, Financial Results, Trust Account, Redemption, Warrants, Shareholders